FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308384309> ?p ?o ?g. }

• W4308384309 abstract "<h3>Background</h3> There is a need to develop novel immunotherapeutic approaches to enhance responses to immune checkpoint blockade. REGN7075 is a human costimulatory bispecific antibody designed to bridge epidermal growth factor receptor (EGFR)-expressing tumor cells with CD28-positive T cells to support further T-cell activation by endogenous tumor antigens [1, 2] (figure 1). We initiated a first-in-human, open-label, Phase 1/2 dose-escalation and expansion study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of REGN7075 (EGFRxCD28) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors (figure 2; NCT04626635). <h3>Methods</h3> We report preliminary results of the dose-escalation phase (Bayesian optimal interval design; Part 1), in which heavily pre-treated patients with advanced solid tumors will receive a lead-in of REGN7075 monotherapy every week for 3 weeks, followed by combination therapy with cemiplimab 350mg every 3 weeks. Planned dose levels (DL) of REGN7075 are 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300, and 900mg. Primary objective is to assess safety and tolerability of REGN7075 in combination with cemiplimab. <h3>Results</h3> As of the data cutoff date (May 6, 2022), 18 patients (median age, 53.5 years, 56% female) were treated in the dose-escalation phase (table 1), up to the 30mg DL for REGN7075 in combination with cemiplimab. Most patients (67%) were treated for microsatellite stable colorectal cancer. No patients experienced dose-limiting toxicities; maximum tolerated dose was not reached. Table 2 summarizes treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). The most frequent TEAEs (any grade) were increases in aspartate aminotransferase (AST), constipation, and fatigue (33% [n=6] each). The most frequent TRAEs (any grade) were fatigue (17% [n=3]), increases in AST, diarrhea, hypothyroidism, pyrexia, and rash (11% [n=2] each). One patient developed cytokine release syndrome which was characterized by isolated grade 1 fever without hypotension nor hypoxia. Five recorded deaths were not during study treatment and not attributed to study drug(s). Ongoing PK evaluation suggests possible target-mediated effects. T cell activation-associated cytokines were detected in monotherapy lead-in and combination dosing. Of all patients treated, 1 patient who received 1mg REGN7075 with cemiplimab for cervical cancer achieved an ongoing partial response. <h3>Conclusions</h3> In this dose-escalation study, REGN7075 was safely administered up to the 30mg dose level in combination with cemiplimab without dose-limiting toxicities. Early data indicates that novel agent REGN7075 was generally well tolerated, with preliminary potential anti-tumor activity. Biomarker studies are ongoing. Clinical trial enrollment is ongoing; we are currently evaluating the 100mg cohort. <h3>Acknowledgements</h3> This study was funded by Regeneron Pharmaceuticals, Inc. Medical writing support and typesetting was provided by John G Facciponte, PhD, of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc. <h3>Trial Registration</h3> NCT04626635 <h3>Ethics Approval</h3> The protocol and all amendments were approved by the appropriate institutional review board or independent ethics committee at each participating study site. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. <h3>Consent</h3> Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review upon request." @default.
• W4308384309 created "2022-11-11" @default.
• W4308384309 creator A5000594662 @default.
• W4308384309 creator A5003770647 @default.
• W4308384309 creator A5020082347 @default.
• W4308384309 creator A5026335885 @default.
• W4308384309 creator A5031475492 @default.
• W4308384309 creator A5051070723 @default.
• W4308384309 creator A5051881041 @default.
• W4308384309 creator A5055824335 @default.
• W4308384309 creator A5062202820 @default.
• W4308384309 creator A5072271778 @default.
• W4308384309 creator A5073397759 @default.
• W4308384309 creator A5073970384 @default.
• W4308384309 creator A5076736008 @default.
• W4308384309 creator A5079585504 @default.
• W4308384309 creator A5085856366 @default.
• W4308384309 date "2022-11-01" @default.
• W4308384309 modified "2023-09-26" @default.
• W4308384309 title "735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results" @default.
• W4308384309 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0735" @default.
• W4308384309 hasPublicationYear "2022" @default.
• W4308384309 type Work @default.
• W4308384309 citedByCount "0" @default.
• W4308384309 crossrefType "proceedings-article" @default.
• W4308384309 hasAuthorship W4308384309A5000594662 @default.
• W4308384309 hasAuthorship W4308384309A5003770647 @default.
• W4308384309 hasAuthorship W4308384309A5020082347 @default.
• W4308384309 hasAuthorship W4308384309A5026335885 @default.
• W4308384309 hasAuthorship W4308384309A5031475492 @default.
• W4308384309 hasAuthorship W4308384309A5051070723 @default.
• W4308384309 hasAuthorship W4308384309A5051881041 @default.
• W4308384309 hasAuthorship W4308384309A5055824335 @default.
• W4308384309 hasAuthorship W4308384309A5062202820 @default.
• W4308384309 hasAuthorship W4308384309A5072271778 @default.
• W4308384309 hasAuthorship W4308384309A5073397759 @default.
• W4308384309 hasAuthorship W4308384309A5073970384 @default.
• W4308384309 hasAuthorship W4308384309A5076736008 @default.
• W4308384309 hasAuthorship W4308384309A5079585504 @default.
• W4308384309 hasAuthorship W4308384309A5085856366 @default.
• W4308384309 hasBestOaLocation W43083843091 @default.
• W4308384309 hasConcept C126322002 @default.
• W4308384309 hasConcept C143998085 @default.
• W4308384309 hasConcept C159654299 @default.
• W4308384309 hasConcept C197934379 @default.
• W4308384309 hasConcept C203014093 @default.
• W4308384309 hasConcept C2778375690 @default.
• W4308384309 hasConcept C71924100 @default.
• W4308384309 hasConceptScore W4308384309C126322002 @default.
• W4308384309 hasConceptScore W4308384309C143998085 @default.
• W4308384309 hasConceptScore W4308384309C159654299 @default.
• W4308384309 hasConceptScore W4308384309C197934379 @default.
• W4308384309 hasConceptScore W4308384309C203014093 @default.
• W4308384309 hasConceptScore W4308384309C2778375690 @default.
• W4308384309 hasConceptScore W4308384309C71924100 @default.
• W4308384309 hasLocation W43083843091 @default.
• W4308384309 hasOpenAccess W4308384309 @default.
• W4308384309 hasPrimaryLocation W43083843091 @default.
• W4308384309 hasRelatedWork W1556562895 @default.
• W4308384309 hasRelatedWork W2057339290 @default.
• W4308384309 hasRelatedWork W2087016115 @default.
• W4308384309 hasRelatedWork W2160729253 @default.
• W4308384309 hasRelatedWork W2335774562 @default.
• W4308384309 hasRelatedWork W2349164817 @default.
• W4308384309 hasRelatedWork W2363981502 @default.
• W4308384309 hasRelatedWork W2409130183 @default.
• W4308384309 hasRelatedWork W3189762672 @default.
• W4308384309 hasRelatedWork W4251165208 @default.
• W4308384309 isParatext "false" @default.
• W4308384309 isRetracted "false" @default.
• W4308384309 workType "article" @default.